We aimed to identify whether N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) at peak exercise can provide incremental clinical information over resting levels. A total of 90 patients with systolic heart failure were prospectively studied. Levels of plasma NT-proBNP were assessed at rest and at peak exercise during a cardiopulmonary exercise test. Patients were followed-up for 30 ± 10 months. Levels of NT-proBNP at baseline and peak exercise were significantly correlated with left ventricular ejection fraction ([LVEF] r = −.629, P < .001 and r = −.630, P < .001, respectively) and peak oxygen uptake ([Vo2] r = −.752, P < .001 and r = −.740, P < .001, respectively). Levels of plasma NT-proBNP at peak exercise demonstrated similar predictive ability for the detection of patients with low peak Vo2 and LVEF <28%. Levels of plasma NT-proBNP can detect low-functional class patients and patients who may be the candidates for heart transplantation with high sensitivity and specificity. At baseline and peak exercise, NT–proBNP demonstrates similar prognostic and predictive ability.
RichardsAMDoughtyRNichollsMG. Australia-New Zealand Heart Failure Group Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37(7):1781–1787.
2.
NishikimiTMorimotoAIshikawaK. Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. Clin Exp Hypertens. 1997;19(4):503–518.
3.
KohnoMYasunariKYokokawaK. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy. Metabolism. 1996;45(11):1326–1329.
4.
WinHKChangSMRainzerM. Percent change in B type natriuretic peptide levels during treadmill exercise as a screening test for exercise induced myocardial ischemia. Am Heart J. 2005;150(4):695–700.
5.
KallistratosMSDritsasALaoutarisIDCokkinosDV. No incremental clinical information of NT-proBNP at peak exercise over resting levels in patients with impaired left ventricular function. Int J Cardiol. 2007;121(2):221–223.
6.
OtsukaTKawadaTSeinoYIbukiCKatsumataMKodaniE. Relation of smoking status to serum levels of N-terminal pro-brain natriuretic peptide in middle-aged men without overt cardiovascular disease. Am J Cardiol. 2010;106(10):1456–1460.
7.
Lara FernandesJSerranoCVJrToledoF. Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease. Clin Res Cardiol. 2011;100(1):77–84.
8.
BorlaugBANishimuraRASorajjaPLamCSRedfieldMM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588–595.
9.
PagoureliasEDGiannoglouGKouidiE. Brain natriuretic peptide and the athlete's heart: a pilot study. Int J Clin Pract. 2010;64(4):511–517.
10.
KrupickaJJanotaTKasalováZHradecJ. Effect of short-term maximal exercise on BNP plasma levels in healthy individuals. Physiol Res. 2010;59(4):625–628.
11.
SmartNMeyerTButterfieldJ. Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. Eur J Cardiovasc Prev Rehabil. 2011. doi: 10.1177/1741826711409171;
12.
ManciniDMEisenHKussmaulWMullREdmundsLHJrWilsonJR. Value of peak exercise consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778–786.
13.
ManciniDLeJemtelTAaronsonK. Peak Vo2: a simple yet enduring standard. Circulation. 2000;101(10):1080–1082.
14.
PardaensKVan CleemputJVanhaeckeJFagardRH. Peak oxygen uptake better predicts outcome than submaximal respiratory data in heart transplant candidates. Circulation. 2000;101(10):1152–1157.
15.
RileyMNorthridgeDBHendersonEStanfordCFNicholsDPDargieHJ. The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic cardiac failure. Eur Heart J. 1992;13(10):1363–1367.
16.
WuAHSmithAWieczorekS. Biological variation for N-terminal pro and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive Heart Failure. Am J Cardiol. 2003;92(5):628–631.
17.
KimHChoYKJunDH. Prognostic implications of the NT-ProBNP level and left atrial size in non-ischemic dilated cardiomyopathy. Circ J. 2010;74(10):998–1005.
18.
JernbergTStridsbergMVengePLindahlB. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40(3):437–445.
19.
GroenningBANilssonJCSondergaardL. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 2002;143(5):923–929.
20.
PassinoCPolettiRBramantiFPronteraCClericoAEmdinM. Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail. 2006;8(1):46–53.
21.
WilliamsSGNgLLO'BrienRJTaylorSWrightDJTanLB. Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESHBNP study. Eur J Heart Fail. 2004;6(7):891–900.
22.
WilliamsSGNgLLO'BrienRJ. Complementary roles of simple variables, NYHA and N-BNP, in indicating aerobic capacity and severity of heart failure. Int J Cardiol. 2005;102(2):279–286.
23.
KallistratosMSDritsasALaoutarisIDCokkinosDV. Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients. J Heart Lung Transplant. 2008;27(11):1251–1256.
24.
KallistratosMSDritsasALaoutarisIDCokkinosDV. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance. J Heart Lung Transplant. 2007;26(5):516–521.
25.
KoçMBozkurtAAcartürkESahinDYUnalI. Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure. Am J Cardiol. 2008;101(8):1157–1162.
26.
de GrootePSoudanBLamblinN. Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure?. Am Heart J. 2004;148(2):349–355.
27.
MaederMWolberTRickliH. B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. Int J Cardiol. 2007;120(3):391–398.
28.
PassinoCPolettiRBramantiFPronteraCClericoAEmdinM. Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail. 2006;8(1):46–53.
29.
KallistratosMSDritsasALaoutarisIDCokkinosDV. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol. Angiology. 2008;59(3):323–328.
30.
TalwarSSquireIBDowniePF. Profile of N-terminal pro BNP following acute myocardial infarction: correlation with left ventricular systolic function. Eur Heart J. 2000;21(18):1514–1521.
31.
TsutamotoTWadaAMaedaK. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J. 1997;134(5 pt 1):910–916.
32.
Costello-BoerrigterLCBoerrigterGRedfieldMM. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2):345–353.
